Assenagon Asset Management S.A. Acquires 19,741 Shares of IDEXX Laboratories, Inc. $IDXX

Assenagon Asset Management S.A. grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 35.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,609 shares of the company’s stock after acquiring an additional 19,741 shares during the period. Assenagon Asset Management S.A. owned about 0.09% of IDEXX Laboratories worth $51,152,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its stake in IDEXX Laboratories by 2.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after purchasing an additional 15 shares during the period. MassMutual Private Wealth & Trust FSB boosted its stake in IDEXX Laboratories by 4.4% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after purchasing an additional 16 shares during the period. Moss Adams Wealth Advisors LLC boosted its stake in IDEXX Laboratories by 3.3% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock worth $337,000 after purchasing an additional 17 shares during the period. CWA Asset Management Group LLC grew its holdings in IDEXX Laboratories by 3.5% during the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after buying an additional 17 shares in the last quarter. Finally, Private Trust Co. NA grew its holdings in IDEXX Laboratories by 9.4% during the 3rd quarter. Private Trust Co. NA now owns 209 shares of the company’s stock valued at $134,000 after buying an additional 18 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

IDXX has been the topic of several research analyst reports. UBS Group lowered their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Piper Sandler cut their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. BTIG Research reduced their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Barclays decreased their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Stock Down 1.4%

NASDAQ IDXX opened at $570.21 on Wednesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The company has a market capitalization of $45.34 billion, a P/E ratio of 43.63, a P/E/G ratio of 3.51 and a beta of 1.66. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The stock has a 50 day moving average price of $639.93 and a 200-day moving average price of $663.76.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In related news, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the transaction, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director directly owned 648 shares in the company, valued at $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 45,957 shares of company stock worth $29,862,109. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.